CDK2 inhibition causes anaphase catastrophe in lung cancer through the centrosomal protein CP110

Cancer Research

Volumn 75, Issue 10, 2015, Pages 2029-2038

  Hu, Shanhu ^a,b   Danilov, Alexey V ^a,b   Godek, Kristina ^a,b   Orr, Bernardo ^a,b   Tafe, Laura J ^a,b   Rodriguez Canales, Jaime ^c   Behrens, Carmen ^c   Mino, Barbara ^c   Moran, Cesar A ^c   Memoli, Vincent A ^a,b   Mustachio, Lisa Maria ^a,b   Galimberti, Fabrizio ^a,b   Ravi, Saranya ^a,b   De Castro, Andrew ^a,b   Lu, Yun ^a,b   Sekula, David ^a,b   Andrew, Angeline S ^a,b   Wistuba, Ignacio I ^c   Freemantle, Sarah ^a,b   Compton, Duane A ^a,b   Dmitrovsky, Ethan ^a,b,c   more..

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; CENTROSOMAL PROTEIN CP110; CYCLIN DEPENDENT KINASE 2; CYTOCHROME C; MESSENGER RNA; ROSCOVITINE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CCP110 PROTEIN, HUMAN; CDK2 PROTEIN, HUMAN; CELL CYCLE PROTEIN; KRAS PROTEIN, HUMAN; MICROTUBULE ASSOCIATED PROTEIN; ONCOPROTEIN; PHOSPHOPROTEIN; PURINE DERIVATIVE; RAS PROTEIN;

ANAPHASE CATASTROPHE; ANIMAL CELL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL DIVISION; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME INHIBITION; ENZYME REPRESSION; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; INCUBATION TIME; LIVE CELL IMAGING; LUNG CANCER; LUNG CANCER CELL LINE; MOLECULAR DYNAMICS; MOUSE; MUTATIONAL ANALYSIS; NONHUMAN; ONCOGENE K RAS; PHARMACOGENETICS; PRIORITY JOURNAL; PROCEDURES CONCERNING CELLS; PROTEIN PHOSPHORYLATION; UPREGULATION; WILD TYPE; ANAPHASE; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; GENETICS; LUNG NEOPLASMS; METABOLISM; MUTATION; TUMOR CELL LINE;

ANAPHASE; ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE 2; HUMANS; LUNG NEOPLASMS; MICE; MICROTUBULE-ASSOCIATED PROTEINS; MUTATION; PHOSPHOPROTEINS; PROTO-ONCOGENE PROTEINS; PURINES; RAS PROTEINS;

EID: 84942889240     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-1494     Document Type: Article

References (38)

1. Freemantle SJ, Liu X, Feng Q, Galimberti F, Blumen S, Sekula D, et al. Cyclin degradation for cancer therapy and chemoprevention. J Cell Biochem 2007;102:869-77.
2. Hwang HC, Clurman BE. Cyclin E in normal and neoplastic cell cycles. Oncogene 2005;24:2776-86.
3. Fukuse T, Hirata T, Naiki H, Hitomi S, Wada H. Prognostic significance of cyclin E overexpression in resected non-small cell lung cancer. Cancer Res 2000;60:242-4.
4. Ma Y, Fiering S, Black C, Liu X, Yuan Z, Memoli VA, et al. Transgenic cyclin E triggers dysplasia and multiple pulmonary adenocarcinomas. Proc Natl Acad Sci USA 2007;104:4089-94.
5. Galimberti F, Thompson SL, Liu X, Li H, Memoli V, Green SR, et al. Targeting the cyclin E-Cdk-2 complex represses lung cancer growth by triggering anaphase catastrophe. Clin Cancer Res 2010;16:109-20.
6. Roberts PJ, Stinchcombe TE. KRAS mutation: should we test for it, and does it matter? J Clin Oncol 2013;31:1112-21.
7. Galimberti F, Thompson SL, Ravi S, Compton DA, Dmitrovsky E. Anaphase catastrophe is a target for cancer therapy. Clin Cancer Res 2011;17: 1218-22.
8. Ganem NJ, Godinho SA, Pellman D. A mechanism linking extra centrosomes to chromosomal instability. Nature 2009;460:278-82.
9. Levine DS, Sanchez CA, Rabinovitch PS, Reid BJ. Formation of the tetraploid intermediate is associated with the development of cells with more than four centrioles in the elastase-simian virus 40 tumor antigen transgenic mouse model of pancreatic cancer. Proc Natl Acad Sci U S A 1991; 88:6427-31.
10. D'Assoro AB, Barrett SL, Folk C, Negron VC, Boeneman K, Busby R, et al. Amplified centrosomes in breast cancer: a potential indicator of tumor aggressiveness. Breast Cancer Res Treat 2002;75:25-34.
11. Lingle WL, Salisbury JL. Altered centrosome structure is associated with abnormal mitoses in human breast tumors. Am J Pathol 1999;155: 1941-51.
12. Pihan GA, Wallace J, Zhou Y, Doxsey SJ. Centrosome abnormalities and chromosome instability occur together in pre-invasive carcinomas. Cancer Res 2003;63:1398-404.
13. Giehl M, Fabarius A, Frank O, Hochhaus A, Hafner M, Hehlmann R, et al. Centrosome aberrations in chronic myeloid leukemia correlate with stage of disease and chromosomal instability. Leukemia 2005;19: 1192-7.
14. Kwon M, Godinho SA, Chandhok NS, Ganem NJ, Azioune A, Thery M, et al. Mechanisms to suppress multipolar divisions in cancer cells with extra centrosomes. Genes Dev 2008;22:2189-203.
15. Chen Z, Indjeian VB, McManus M, Wang L, Dynlacht BD. CP110, a cell cycle-dependent CDK substrate, regulates centrosome duplication in human cells. Dev Cell 2002;3:339-50.
16. Schmidt TI, Kleylein-Sohn J, Westendorf J, Le Clech M, Lavoie SB, Stierhof YD, et al. Control of centriole length by CPAP and CP110. Curr Biol 2009;19:1005-11.
17. Tsang WY, Spektor A, Luciano DJ, Indjeian VB, Chen Z, Salisbury JL, et al. CP110 cooperates with two calcium-binding proteins to regulate cytokinesis and genome stability. Mol Biol Cell 2006;17:3423-34.
18. Tsang WY, Bossard C, Khanna H, Peränen J, Swaroop A, Malhotra V, et al. CP110 suppresses primary cilia formation through its interaction with CEP290, a protein deficient in human ciliary disease. Dev Cell 2008;15: 187-97.
19. Spektor A, Tsang WY, Khoo D, Dynlacht BD. Cep97 and CP110 suppress a cilia assembly program. Cell 2007;130:678-90.
20. D'Angiolella V, Donato V, Vijayakumar S, Saraf A, Florens L, Washburn MP, et al. SCF (Cyclin F) controls centrosome homeostasis and mitotic fidelity through CP110 degradation. Nature 2010;466:138-42.
21. Le Tourneau C, Faivre S, Laurence V, Delbaldo C, Vera K, Girre V, et al. Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies. Eur J Cancer 2010;46:3243-50.
22. Dragnev KH, Ma T, Cyrus J, Galimberti F, Memoli V, Busch AM, et al. Bexarotene plus erlotinib suppress lung carcinogenesis independent of KRAS mutations in two clinical trials and transgenic models. Cancer Prev Res 2011;4:818-28.
23. Wislez M, Fujimoto N, Izzo JG, Hanna AE, Cody DD, Langley RR, et al. High expression of ligands for chemokine receptor CXCR2 in alveolar epithelial neoplasia induced by oncogenic kras. Cancer Res 2006;66: 4198-207.
24. Petty WJ, Li N, Biddle A, Bounds R, Nitkin C, Ma Y, et al. A novel retinoic acid receptor beta isoform and retinoid resistance in lung carcinogenesis. J Natl Cancer Inst 2005;97:1645-51.
25. Li J, D'Angiolella V, Seeley ES, Kim S, Kobayashi T, Fu W, et al. USP33 regulates centrosome biogenesis via deubiquitination of the centriolar protein CP110. Nature 2013;495:255-9.
26. To MD, Quigley DA, Mao JH, Rosario RD, Hsu J, Hodgson G, et al. Progressive genomic instability in the FVB/KrasLA2 mouse model of lung cancer. Mol Cancer Res 2011;9:1339-1345.
27. Pitha-Rowe I, Hassel BA, Dmitrovsky E. Involvement of UBE1L in ISG15 conjugation during retinoid-induced differentiation of acute promyelocytic leukemia. J Biol Chem 2004;279:18178-87.
28. Crasta K, Ganem NJ, Dagher R, Lantermann AB, Ivanova EV, Pan Y, et al. DNA breaksand chromosomepulverization from errors inmitosis. Nature 2012;482:53-8.
29. Kobayashi T, Dynlacht BD. Regulating the transition from centriole tobasal body. J Cell Biol 2011;193:435-44.
30. Harrison MK, Adon AM, Saavedra HI. The G1 phase Cdks regulate the centrosome cycle and mediate oncogene-dependent centrosome amplification. Cell Div 2011;6:2.
31. Zeng X, Shaikh FY, Harrison MK, Adon AM, Trimboli AJ, Carroll KA, et al. The Ras oncogene signals centrosome amplification in mammary epithelial cells through cyclin D1/Cdk4 and Nek2. Oncogene 2010; 29:5103-12.
32. Castagnola P, Giaretti W. Mutant KRAS, chromosomal instability and prognosis in colorectal cancer. Biochim Biophys Acta 2005;1756: 115-25.
33. Lai Y, Chen B, Shi J, Palmer JN, Kennedy DW, Cohen NA. Inflammation-mediated upregulation of centrosomal protein 110, a negative modulator of ciliogenesis, in patients with chronic rhinosinusitis. J Allergy Clin Immunol 2011;128:1207-1215.
34. Plotnikova OV, Golemis EA, Pugacheva EN. Cell-cycle-dependent ciliogenesis and cancer. Cancer Res 2008;68:2058-61.
35. Michaud EJ, Yoder BK. The primary cilium in cell signaling and cancer. Cancer Res 2006;66:6463-7.
36. Seeley ES, Carriere C, Goetze T, Longnecker DS, Korc M. Pancreatic cancer and precursor pancreatic intraepithelial neoplasia lesions are devoid of primary cilia. Cancer Res 2009;69:422-30.
37. Bukanov NO, Smith LA, Klinger KW, Ledbetter SR, Ibraghimov-Beskrovnaya O. Long-lasting arrest of murine polycystic kidney disease with CDK inhibitor roscovitine. Nature 2006;444: 949-52.
38. Al-Hakim AK, Bashkurov M, Gingras AC, Durocher D, Pelletier L. Interaction proteomics identify NEURL4 and the HECT E3 ligase HERC2 as novel modulators of centrosome architecture. Mol Cell Proteomics 2012;11:M111.014233.